Prognostic Factors in Acute Promyelocytic Leukemia: A Retrospective Study of 67 Cases

References

• Groopman J., Ellman L. Acute promyelocytic leukemia. American Journal of Hematology 1979; 7: 395–408
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M. J., Walters R. S., Estey E. H., McCredie K. C., Smith T. L., Dalton W. T., Cork A., Trujillo J. M., Freireich E. J. Acute promyelocytic leukemia. M. D. Anderson Hospital experience. American Journal of Medicine 1986; 80: 789–97
   PubMed Web of Science ®Google Scholar
• Bernard J., Weil M., Boiron M., Jacquillat C., Flandrin G., Ganem M. F. Acute promyelocytic leukemia: Results of treatment by daunorubicin. Blood 1973; 41: 489–96
   PubMed Web of Science ®Google Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Annals of Internal Medicine 1985; 103: 626–29
   PubMedGoogle Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R. A variant form of hypergranular promyelocytic leukaemia (M3). British Journal of Haematology 1980; 44: 169–70
   PubMed Web of Science ®Google Scholar
• Golomb H. M., Rowley J. D., Vardiman J. W., Testa J. R., Butler A. Microgranular acute promyelocytic leukemia: A distinct clinical, ultrastructural, and cytogenetic entity. Blood 1980; 55: 253–9
   PubMed Web of Science ®Google Scholar
• Larson R. A., Kondo K., Vardiman J. W., Butler A. E., Golomb H. M., Rowley J. D. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. American Journal of Medicine 1984; 76: 827–41
   PubMed Web of Science ®Google Scholar
• Drapkin R. L., Gee T. S., Drowling M. D., Arlin Z., McKenzie S., Kempin S., Clarkson B. Prophylactic heparin therapy in acute promyelocytic leukemia. Cancer 1978; 41: 2484–90
   PubMed Web of Science ®Google Scholar
• Collins A. J., Bloomfield C. D., Paterson B. A., McKenna R. W., Edison J. R. Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicinprednisone induction. Archives of Internal Medicine 1978; 138: 1677–80
   PubMed Web of Science ®Google Scholar
• Di Marco P., Cajozzo A. Acute promyelocytic leukemia: Management of DIC during remission induction (abstr.). Presented at the Third International Symposium on Therapy of acute leukemias, Rome, Italy. 1982
   Google Scholar
• Goldberg M. A., Ginsburg D., Mayer R. J., Stone R. M., Maguire M., Rosenlhal D. S., Antin J. H. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia?. Blood 1987; 69: 187–91
   PubMed Web of Science ®Google Scholar
• Hoyle C. F., Swirsky D. M., Freedman L., Hayhoe G. J. Beneficial effect of heparin in the management of patients with APL. British Journal of Haematology 1988; 68: 283–9
   PubMed Web of Science ®Google Scholar
• Marty M., Ganem G., Fisher J., Flandrin G., Berger R., Schaison G., Degos L., Boiron M. Leucémie aigüe promyélocytaire: Etude rétrospective de 119 malades traités par daunorubicine. Nouvelle Revue Française d'Hématologie 1984; 26: 371–8
   PubMedGoogle Scholar
• Kantarjian H. M., Keating M. J., Walters R. S., Smith T. L., McCredie K. B., Freireich E. J. Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer 1987; 59: 1258–63
   PubMed Web of Science ®Google Scholar
• Dutrillaux B., Lejeune J. Sur une nouvelle technique d'analyse du caryotype humain. Compte rendu de l'Académie des Sciences (Paris) 1971; 272: 2638–40
   Google Scholar
• World Health Organization Handbook for Reporting Results of Cancer Treatment. WHO offset publication 1979; 48, WHO-Geneva
   Google Scholar
• Archimbaud E., Fiere D., Treille-Ritouet D., Adeleine P., Guyotat D., Sebban C., Vuvan H., Viala J. J. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial. Cancer Treatment Reports 1987; 71: 571–4
   PubMedGoogle Scholar
• Fiere D., Bryon P. A., Felman P., Martin C., Peaud P. Y., Revol L. Treatment of adult acute myeloid leukemia. European Journal of Cancer 1977; 13: 403–6
   PubMed Web of Science ®Google Scholar
• Fiere D., Bryon P. A., Felman P., Reynaud Y., Coiffier B., Vuvan H. Massive and intermittent chemotherapy induction in 211 patients with acute myeloid leukemia. Symposium on Acute Myeloid Leukemia. International Society of Haematology. Hamburg 1979, 1979
   Google Scholar
• Zittoun R., Jehn U., Fiere D., Haanen C., Löwenberg B., Willemze R., Abels J., Bury J., Peetermans M., Hayat M., Suciu S., Solbu G., Stryckmans P. Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood 1989; 73: 896–906
   PubMed Web of Science ®Google Scholar
• Ellison R. R., Holland J. F., Weil M., Jacquillat C., Boiron M., Bernard J., Sawitsky A., Rosner F., Gussoff B., Silver R. T., Karanas A., Cuttner J., Spurr C. L., Hayes D. M., Blom J., Leone L. A., Haurani F., Kyle R., Hutchinson J. L., Forcier R. J., Moon J. H. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507–23
   PubMed Web of Science ®Google Scholar
• Preisler H. D. Failure of remission induction during the treatment of acute leukemia. Medical and Pediatric Oncology 1978; 4: 275–6
   PubMedGoogle Scholar
• Second MIC Cooperative Study Group. Morphologic, immunologic, and cytogenetic (MIC) working classification of the acute myeloid leukemias. Report of the Workshop held in Leuven, Belgium September 15–17, 1986. Cancer Genetic Cytogenetic 1988; 30: 1–15
   PubMed Web of Science ®Google Scholar
• Cordonnier C., Vernant J. P., Brun B., Gouault Heilmann M., Kuentz M., Bierling P., Farcet J. P., Rodet M., Duedari N., Imbert M., Jouault H., Mannoni P., Reyes F., Dreyfus B., Rochant H. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985; 55: 18–25
   PubMed Web of Science ®Google Scholar
• Daly P. A., Shiffer C. A., Wiernick P. H. Acute promyelocytic leukemia: Clinical management of 15 patients. American Journal of Hematology 1980; 8: 347–59
   PubMed Web of Science ®Google Scholar
• Sanz M. A., Jarque I., Martin G., Lorenzo I., Martinez J., Rafecas J., Pastor E., Sayas M. J., Sanz G., Gomis F. Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer 1988; 61: 7–13
   PubMed Web of Science ®Google Scholar
• Stone R. M., Maguire M., Goldberg M. A., Antin J. H., Rosenthal D. S., Mayer R. J. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood 1988; 71: 690–6
   PubMed Web of Science ®Google Scholar
• Runde V., Aul C., Landen H., Dikekias A., Fillet G., Schneider W. Acute promyelocytic leukemia: clinical findings and therapeutic results in 30 patients. Hämatologie und Bluttransfusion 1990; 33: 346–50
   Google Scholar
• Fenaux P., Pollet J. P., Vandenbosshe L., Dupriez B., Jouet J. P., Bauters F. Treatment of acute promyelocytic leukemia (APL) with or without AraC and continuous maintenance therapy. Blood 1989; 72: 356a, Suppl. 1
   Google Scholar
• Archimbaud E., Treille-Ritouet D., Guyotat D., Viala J. J., Fiere D. Day 4 bone marrow aspirate for prediction of resistance to induction chemotherapy in acute myeloid leukemia. Leukemia Research 1987; 11: 281–3
   PubMed Web of Science ®Google Scholar
• Wallace P. J. Complete remission in acute promyelocytic leukemia despite the persistence of the 15;17 translocation. American Journal of Hematology 1989; 31: 266–8
   PubMed Web of Science ®Google Scholar
• Arlin Z., Kempin S., Mertelsmann R., Gee T., Higgins C., Jhanvar S., Chaganti R. C. K., Clarkson B. Primary therapy of acute promyelocytic leukemia: Results of amsacrine-and daunorubicin-based therapy. Blood 1984; 63: 211–2
   PubMed Web of Science ®Google Scholar
• Cunningham I., Gee T. S., Reich L. M., Kempin S. J., Naval A. N., Clarkson B. D. Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital. Blood 1989; 73: 1116–22
   PubMed Web of Science ®Google Scholar
• Ganem G., Fischer J., Marty M. Prognostic factors in acute promyelocytic leukemia (APL): A retrospective study of 101 patients treated by DNR containing remission induction regimen. Blood 1983; 62: 171a, Suppl. 1
   Google Scholar
• Huang M. E., Ye Y. C., Chen S. R., Chai J. R., Lu J. X., Zhoa L., Gu L. J., Wang Z. Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–72
   PubMed Web of Science ®Google Scholar